AR 035
Alternative Names: AR-035Latest Information Update: 24 Aug 2021
At a glance
- Originator Arthrosi Therapeutics
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 17 Aug 2021 Arthrosi Therapeutics has formed joint venture with Guangzhou Ruiao Biopharmaceutical Technology forming Guangzhou Ruianbo Pharmaceutical Technology
- 17 Aug 2021 Arthrosi Therapeutics plans a preclinical trials for Non-small cell lung cancer in USA
- 01 Aug 2021 Early research in Non-small cell lung cancer in USA